Urokinase-type plasminogen activator receptor as a potential PET biomarker in glioblastoma

Journal of Nuclear Medicine

Volumn 57, Issue 2, 2016, Pages 272-278

  Persson, Morten ^a   Nedergaard, Mette K ^a,b   Brandt Larsen, Malene ^a   Skovgaard, Dorthe ^a   Jørgensen, Jesper T ^a   Michaelsen, Signe R ^b   Madsen, Jacob ^a   Lassen, Ulrik ^b   Poulsen, Hans S ^b   Kjaer, Andreas ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b FINSEN LABORATORY   (Denmark)

Author keywords

Glioblastoma; PET; PET CT; Survival; Translational; Urokinase type

Indexed keywords

2 (2 FLUOROETHYL)TYROSINE F 18; EOSIN; HEMATOXYLIN; MESSENGER RNA; NOTA AE105 CU 64; NOTA AE105 GA 68; RADIOPHARMACEUTICAL AGENT; TEMOZOLOMIDE; UNCLASSIFIED DRUG; UROKINASE RECEPTOR; COPPER; TUMOR MARKER;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BIOLUMINESCENCE; CANCER GROWTH; CANCER LOCALIZATION; CANCER PATIENT; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; ISOTOPE LABELING; MALE; MIDDLE AGED; MOUSE; MULTIPLE CYCLE TREATMENT; NEUROSURGERY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT; ANIMAL; BIOSYNTHESIS; BRAIN TUMOR; CELL CULTURE; DRUG SCREENING; METABOLISM; SCINTISCANNING; SURVIVAL ANALYSIS;

ADULT; ANIMALS; AUTORADIOGRAPHY; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; CELLS, CULTURED; COPPER RADIOISOTOPES; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MICE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; RNA, MESSENGER; SURVIVAL ANALYSIS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84958611363     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.115.161703     Document Type: Article

References (37)

1. Clarke J, Butowski N, Chang S. Recent advances in therapy for glioblastoma. Arch Neurol. 2010;67:279-283.
2. Michaelsen SR, Christensen IJ, Grunnet K, et al. Clinical variables serve as prognostic factors in a model for survival from glioblastoma multiforme: an observational study of a cohort of consecutive nonselected patients from a single institution. BMC Cancer. 2013;13:402.
3. Desjardins A, Friedman HS. Neuro-oncology: glioblastoma-community adjusts to new standard of care. Nat Rev Neurol. 2012;8:244-246.
4. 18F-FET PET in newly diagnosed cerebral lesions suggestive of glioma. J Nucl Med. 2013;54:229-235.
5. Gulyás B, Halldin C. New PET radiopharmaceuticals beyond FDG for brain tumor imaging. Q J Nucl Med Mol Imaging. 2012;56:173-190.
6. Alexiou GA, Tsiouris S, Voulgaris S, Kyritsis AP, Fotopoulos AD. Glioblastoma multiforme imaging: the role of nuclear medicine. Curr Radiopharm. 2012;5:308-313.
7. 18F]39-deoxy-39-fluorothymidine PET for the diagnosis and graDing of brain tumors. Eur J Nucl Med Mol Imaging. 2005;32:653-659.
8. 18F-fluorothymidine PET-derived proliferative volume predicts overall survival in high-grade glioma patients. J Nucl Med. 2012;53:1904-1910.
9. 18F-fluoroethyl)-L-tyrosine PET as a diagnostic tool for detection of malignant progression in patients with low-grade glioma. J Nucl Med. 2013;54:2046-2054.
10. 18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma. Neuro-Oncol. 2013;15:341-351.
11. 18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival. Clin Cancer Res. 2008;14:2623-2630.
12. 18F-fluoromisonidazole positron emission tomography may differentiate glioblastoma multiforme from less malignant gliomas. Eur J Nucl Med Mol Imaging. 2012;39:760-770.
13. Persson M, Kjaer A. Urokinase-type plasminogen activator receptor (uPAR) as a promising new imaging target: potential clinical applications. Clin Physiol Funct Imaging. 2013;33:329-337.
14. Li D, Liu S, Shan H, Conti P, Li Z. Urokinase plasminogen activator receptor (uPAR) targeted nuclear imaging and radionuclide therapy. Theranostics. 2013;3:507-515.
15. Rasch MG, Lund IK, Almasi CE, Hoyer-Hansen G. Intact and cleaved uPAR forms: diagnostic and prognostic value in cancer. Front Biosci. 2008;13:6752-6762.
16. Jacobsen B, Ploug M. The urokinase receptor and its structural homologue C4.4A in human cancer: expression, prognosis and pharmacological inhibition. Curr Med Chem. 2008;15:2559-2573.
17. de Bock CE, Wang Y. Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer. Med Res Rev. 2004;24:13-39.
18. Salajegheh M, Rudnicki A, Smith TW. Expression of urokinase-type plasminogen activator receptor (uPAR) in primary central nervous system neoplasms. Appl Immunohistochem Mol Morphol. 2005;13:184-189.
19. Mohanam S, Gladson CL, Rao CN, Rao JS. Biological significance of the expression of urokinase-type plasminogen activator receptors (uPARs) in brain tumors. Front Biosci. 1999;4:D178-D187.
20. Yamamoto M, Sawaya R, Mohanam S, et al. Expression and localization of urokinase-type plasminogen activator receptor in human gliomas. Cancer Res. 1994;54:5016-5020.
21. Wykosky J, Hu J, Gomez GG, et al. A urokinase receptor-Bim signaling axis emerges during EGFR inhibitor resistance in mutant EGFR glioblastoma. Cancer Res. 2015;75:394-404.
22. Persson M, Madsen J, Jørgensen TJD, Jensen KJ, Kjaer A, Ploug M. Improved PET imaging of uPAR expression using new 64Cu-labeled cross-bridged peptide ligands: comparative in vitro and in vivo studies. Theranostics. 2013;3:618-632.
23. 18F-labeled ligand for PET imaging of uPAR: in vivo studies in human prostate cancer xenografts. Nucl Med Biol. 2013;40:618-624.
24. 68Ga-labeling and in vivo evaluation of a uPAR binDing DOTA-and NODAGA-conjugated peptide for PET imaging of invasive cancers. Nucl Med Biol. 2012;39:560-569.
25. Persson M, Madsen J, Ostergaard S, et al. Quantitative PET of human urokinasetype plasminogen activator receptor with 64Cu-DOTA-AE105: implications for visualizing cancer invasion. J Nucl Med. 2012;53:138-145.
26. Ploug M, Ostergaard S, Gardsvoll H, et al. Peptide-derived antagonists of the urokinase receptor. affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation. Biochemistry. 2001;40:12157-12168.
27. Cekanova M, Rathore K. Animal models and therapeutic molecular targets of cancer: utility and limitations. Drug Des Devel Ther. 2014;8:1911-1921.
28. Stockhausen MT, Broholm H, Villingshoj M, et al. Maintenance of EGFR and EGFRvIII expressions in an in vivo and in vitro model of human glioblastoma multiforme. Exp Cell Res. 2011;317:1513-1526.
29. 18F-FET microPET imaging to evaluate response to irinotecan in orthotopic human glioblastoma multiforme xenografts. PLoS One. 2014;9:e100009.
30. Jacobsen B, Gardsvoll H, Juhl Funch G, Ostergaard S, Barkholt V, Ploug M. One-step affinity purification of recombinant urokinase-type plasminogen activator receptor using a synthetic peptide developed by combinatorial chemistry. Protein Expr Purif. 2007;52:286-296.
31. Lin L, Gardsvoll H, Huai Q, Huang M, Ploug M. Structure-based engineering of species selectivity in the interaction between urokinase and its receptor: implication for preclinical cancer therapy. J Biol Chem. 2010;285:10982-10992.
32. Illemann M, Bird N, Majeed A, et al. Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases. Int J Cancer. 2009;124:1860-1870.
33. Rønne E, Hoyer-Hansen G, Brunner N, et al. Urokinase receptor in breast cancer tissue extracts: enzyme-linked immunosorbent assay with a combination of mono-and polyclonal antibodies. Breast Cancer Res Treat. 1995;33:199-207.
34. MacDonald TJ, DeClerck YA, Laug WE. Urokinase induces receptor mediated brain tumor cell migration and invasion. J Neurooncol. 1998;40:215-226.
35. Zhang X, Fei Z, Bu X, et al. Expression and significance of urokinase type plasminogen activator gene in human brain gliomas. J Surg Oncol. 2000;74:90-94.
36. Fung AS, Lee C, Yu M, Tannock IF. The effect of chemotherapeutic agents on tumor vasculature in subcutaneous and orthotopic human tumor xenografts. BMC Cancer. 2015;15:112.
37. 18F]-FLT PET in patients with high-grade gliomas. PLoS One. 2014;9:e95830.